Lion Street Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Lion Street Advisors's VRTX Position: Q3 2025 in Review
Lion Street Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 142% in Q3 2025, buying an estimated $352K and bringing the position to 1,435 shares worth $265K. The position accounts for 0.09% of the portfolio, ranked #173.
Lion Street Advisors first reported a position in VRTX in Q1 2020 and has held it in 16 quarters since. The position peaked at $332K in Q1 2022. 1,519 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.
- Lion Street Advisors held 1,435 shares of Vertex Pharmaceuticals worth $265K as of Q3 2025.
- Lion Street Advisors bought 843 Vertex Pharmaceuticals shares in Q3 2025, an estimated $352K.
- Vertex Pharmaceuticals made up 0.09% of Lion Street Advisors's portfolio in Q3 2025, its #173 holding.
- Lion Street Advisors first reported a position in Vertex Pharmaceuticals in Q1 2020 and has held it in 16 quarters since.
- Lion Street Advisors's Vertex Pharmaceuticals position peaked at $332K in Q1 2022.
- 1,519 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.
Based on Lion Street Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.